Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-LAIR1 monoclonal antibody NC525

A humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against leukocyte-associated immunoglobulin-like receptor 1 (LAIR1; LAIR-1; CD305), with potential antineoplastic activity. Upon administration, anti-LAIR1 monoclonal antibody NC525 targets, binds to and inhibits LAIR1-mediated downstream survival signaling. In addition, NC525 induces Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This inhibits survival of LAIR1-expressing acute myeloid leukemia (AML) leukemic stem cells (LSCs) and blast cells, and decreases tumor cell proliferation. LAIR1, an immune inhibitory checkpoint receptor, is overexpressed in AML LSCs and blast cells while having a minimal expression on normal, healthy hematopoietic stem cells (HSCs.). LAIR1 plays a key role in mediating survival signaling in these tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-LAIR-1 monoclonal antibody NC525
Code name:NC 525
NC-525
NC525
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search